Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Short-Term Xenical Treatment Benefits “Difficult To Define,” FDA Says

This article was originally published in The Tan Sheet

Executive Summary

Efficacy concerns surrounding GlaxoSmithKline's Xenical (orlistat) may prove to be a bigger hurdle to overcome than safety or self-selection issues as the firm pursues an Rx-to-OTC switch of the drug
Advertisement

Related Content

Glaxo’s Alli Advances Toward OTC Sale With “Approvable” Letter
Glaxo’s Alli Advances Toward OTC Sale With “Approvable” Letter
Glaxo’s Alli Advances Toward OTC Sale With “Approvable” Letter
Alli Sparks Reevaluation Of OTC Weight-Loss Indication
Alli Sparks Reevaluation Of OTC Weight-Loss Indication
Alli Sparks Reevaluation Of OTC Weight-Loss Indication
GSK Sees Big Opportunity In OTC Diet Aids: Xenical Switch NDA Filed
GSK Sees Big Opportunity In OTC Diet Aids: Xenical Switch NDA Filed
Xenical Rx-To-OTC Switch In The Works, GSK/Roche Announce

Topics

Advertisement
UsernamePublicRestriction

Register

PS099035

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel